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The tegument of bovine herpesvirus-1 (BHV-I) carries an abundant protein of 96 kDa, termed VP8. Immunolabeling using 
VP8-specific antiserum and colloidal gold-labeled protein A as the electron-dense marker was used to identify VP8 in the 
virions and virus-infected cells. VP8 was confirmed to be a tegument protein that, like the herpes simplex virus-1 homologue 
VP13/14, contains O-linked carbohydrates. VP8 was found in the nucleus of virus-infected cells as early as 2 hr postinfection. 
Since VP8 is a gamma2 protein, this protein cannot be newly synthesized at this time and must be acquired from the 
inoculum. This supports the hypothesis that early during infection, VP8 has a function in modulation of alpha gene expression. 
Later during infection, VP8 was observed in the cytoplasm around nucleocapsids and in dense inclusions, which accumulated 
in the cisternae of the Golgi. In addition, de novo-synthesized VP8 continued to accumulate in the nucleus in dense areas 
and around nucleocapsids. In calves, VP8 stimulated T cell proliferation and antibody production, both after BHV-1 challenge 
and after immunization with purified VP8. These results suggest a role for VP8 in the induction of humoral and specifically 
cell-mediated immunity to BHV-1. © 1995 Academic Press, inc. 
INTRODUCTION 
Bovine herpesvirus-1 (BHV-1) specifies more than 25 
structural polypeptides (Pastoret eta/., 1980; Misra et a/., 
1981). Three major glycoproteins, which constitute part 
0fthe virion envelope, have been extensively studied (van 
Drunen Littel-van den Hurk and Babiuk, 1986b). These 
glycoproteins, designated gl (gB), gill (gC), and glV (gD), 
are among the most prominent of the proteins recognized 
serologically by BHV-l-infected animals (Collins eta/., 
1985; van Drunen Littel-van den Hurk and Babiuk, 1986a). 
Glycoprotein IV, but not gl and gill, is also consistently 
recognized by CD4 + helper T lymphocytes from BHV-1 
immune cattle (Hutchings eta/., 1990). A number of func- 
tions have been ascribed to these glycoproteins, includ- 
ing virus attachment to gl, gill, and glV (Liang eta/., 1991 ), 
penetration to gl and glV (Hughes et aL, 1988; Fehler et 
a/., 1992), and cell fusion to gl and glV (Fitzpatrick et aL, 
1988, 1990; van Drunen Littel-van den Hurk et aL, 1992; 
Tikoo etaL, 1990). Any one of these glycoproteins, alone 
or in combination, induces protection against BHV-1 in- 
fection in cattle (Babiuk et aL, 1987; van Drunen Littel- 
van den Hurk etaL, 1990). 
The proteins present in the tegument and nucleocap- 
sid of BHV-1 have been poorly characterized. Tegument 
proteins have been defined as those that are neither 
totally released by nonionic detergent solubilization of 
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the lipid envelope of mature intact virus particles, nor 
found associated with the nucleocapsids (Spear and 
Roizman, 1972). In herpes simplex virus (HSV), four tegu- 
ment proteins have been identified and designated VP1/ 
2, VP13/14, VP16, and VP22 (Spear and Roizman, 1972; 
Meredith et aL, 1991). Various functions have been as- 
signed to tegument proteins, including protein kinase 
activity (Lemaster and Roizman, 1980), trans-acting stim- 
ulation of immediate-early gene transcription (Campbell 
eta/., 1984), inhibition of host cell peptide synthesis (Fen- 
wick and Walker, 1978), and degradation of host cell 
mRNA (Schek and Bachenheimer, 1985). There is also 
evide.nce that VP13/14 and VP22 associate with the nu- 
clear matrix during the virus replication cycle (Pinard et 
a/., 1987) and that they are able to bind HSV DNA (Blair 
and Honess, 1983). 
One of the most abundant proteins in BHV-1 virions 
and virus-infected cells is a tegument protein of 96 
kDa, designated VP8 (Misra et aL, 1981), VP7 (Pas~- 
oret et aL, 1980), 91K (Collins et al., 1984), or 107K 
(Marshall et al., 1986). The derived amino acid se- 
quence of the VP8 gene has considerable homology 
with that of HSV-1 UL47, which codes for VP13/14 
(McGeoch et al., 1988; Carpenter and Misra, 1991; 
Laboissiere et aL, 1992). VP13/14 is phosphorylated 
and glycosylated (Meredith et al., 1991). It has been 
shown to modulate alpha-transinducing factor-depen- 
dent induction of alpha genes (McKnight etaL, 1987; 
Zhang et al., 1991). VP8 is also phosphorylated (Car- 
penter and M isra, 1991). However, the function of VP8 
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and the biological relevance of its abundance is not 
understood. Preliminary evidence suggests that VP8 
may be a target for BHV-1 specific immune responses 
in infected cattle (Collins eta/.,  1985; van Drunen Lit- 
tel-van den Hurk and Babiuk, 1986a; Hutchings eta/.,  
1990). 
The purpose of the present study was to further 
elucidate the functions of VP8, both in the infected cell 
and in the host animal. To that end, we determined the 
localization of VP8 in the virus and virus-infected cells 
at the ultrastructural level, as well as identified the 
type of immune responses induced by VP8 in cattle. 
MATERIALS AND METHODS 
Cells and virus 
Strain P8-2 of BHV-1 was propagated in Madin 
Darby bovine kidney (MDBK) cells grown in Eagle 
minimal essential medium (GIBCO Laboratories, 
Grand Island, NY) supplemented with 10% fetal bovine 
serum (FBS) (GIBCO). Virus was purified on potassium 
tartrate gradients as described previously (van Dru- 
nen Littel-van den Hurk and Babiuk, 1985). Purified 
virus was treated with 1% nonidet P-40 (NP-40) or 
with 1% NP-40 and 1 M NaCI in TNE (0.1 M Tr is-  
hydrochloride, 0.15 M NaCI, 0.001 M EDTA, pH 7.5). 
The detergent treated virus was centrifuged for 1 hr 
at 25,000 rpm in a SW 50.1 rotor (Beckman model L8- 
55, Beckman Instruments, Missisauga, ON, Canada). 
The supernatant was collected and the pellet was 
resuspended in TNE. 
Polyacrylamide gel electrophoresis (PAGE) and 
Western blotting 
Affinity-purified VP8 or gradient-purified BHV-1 was 
suspended in electrophoresis sample buffer (0.0625 M 
Tris-HCI (pH 6.8), 1.25% sodium dodecyl sulphate (SDS), 
12.5% glycerol, 0.15 M 2-meroaptoethanol, 0.00125% bro- 
mophenol blue) and boiled for 2 min. The viral proteins 
were separated on a 8.5% discontinuous polyacrylamide 
gel. For Western blotting the proteins were subsequently 
transferred to nitrocellulose in a mini-transblot cell 
(Hoefer Scientific, San Francisco, CA) at 100 V for 45 min 
in 25 mM Tris, 192 mM glycine (pH 8.3), 20% methanol. 
The nitrocellulose was then cut into 5-mm-wide strips 
and assayed for reactivity of BHV-1 hyperimmune or VP8- 
specific bovine sera by following the instructions sup- 
plied with the Bio-Rad immunoblot assay kit. BHV-1 hy- 
perimmune sera were tested for reactivity with VP8, 
whereas VP8-specific sera were tested for reactivity with 
BHV-1 polypeptides. 
I mmunoprecipitation 
The procedure for immunoprecipitation has been de- 
scribed in detail previously (van Drunen Littel-van den 
Hurk et aL, 1984). Briefly, BHV-l-infected and mock-in- 
fected MDBK cell lysates were incubated with bovine 
sera overnight at 4 °, before addition of rabbit IgG anti- 
bovine Ig (Kirkegaard and Perry Laboratories, Gaithers- 
burg, MD). After a 4 hr incubation at 4 ° , immune com- 
plexes were precipitated with Protein A CL-4B (Phar- 
macia, Bale d'Urfe, Quebec, Canada) and analyzed by 
S DS- PAGE. 
Detection of carbohydrate 
VP8 was purified by immunoadsorbent chromatogra- 
phy from BHV-l-infected MDBK cells as described pre- 
viously (van Drunen Littel-van den Hurk and Babiuk, 
1985). Subsequently, the purified VP8 was applied to ni- 
trocellulose by SDS-PAGE and Western blotting. Carbo- 
hydrate was detected on VP8 using two approaches. 
First, carbohydrate on VP8 was oxidized with periodate 
followed by incorporation of biotin using biotin-hydrazide 
(Glycotrack kit, Oxford Biosystems Ltd., Rosedale, NY). 
Second, VP8 was incubated with a range of different 
biotinylated lectins (Sigma, Missisauga, ON, Canada; 
Boehringer-Mannheim, Laval, PQ, Canada). Biotinylated 
compounds were detected with streptavidin-alkaline 
phosphatase conjugate (Bio-Rad, Mississauga, ON, 
Canada). 
VP8-specific antibodies 
A VP8-specific monoclonal antibody (1G4) was raised 
by immunization of mice with purified BHV-1, as de- 
scribed previously (Van Drunen Littel-van den Hurk et 
al., 1984). VP8-specific polyclonal antibodies were raised 
by immunizing rabbits with VP8, purified by affinity chro- 
matography on the VP8-specific monoclonal antibody 
column (Van Drunen Littel-van den Hurk and Babiuk, 
1985), followed by preparative PAGE. The rabbits were 
immunized twice with 50 #g of pure VP8 in Freunds' 
adjuvant. 
Immunofluorescence 
The presence of VP8 in BHV-l-infected cells was de- 
termined at different times postinfectien. MDBK cells 
were infected with BHV-1 at an m.o.i, of 10. At different 
times after infection, the cells were gently trypsinized 
and suspended in MEM with 10% FBS. Cytospin smears 
were prepared and fixed in methanol. They were incu- 
bated for 1 hr at 37 ° with a 1=20 dilution of VP8-specific 
rabbit serum or with a 1=100 dilution of a glV-specific 
monoclonal antibody mixture (Hughes et al., 1988). After 
two washes in PBS and double-distilled water, the ceils 
were stained with fluorescein isothiocyanate-conjugated 
goat anti-rabbit IgG or rabbit anti-mouse IgG (Boehringer- 
Mannheim, Laval, PQ, Canada) for 1 hr at 37 ° and washed 
again before being mounted in PBS-glycerol for exami- 
nation. 
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Electron microscopy and protein A-gold (PAG) 
immunolabeling 
For transmission electron microscopy, MDBK cells 
were infected with BHV-1 at an m.o.i, of 10. At 24 hr 
postinfection, the cell monolayers were fixed for 1 hr 
with 4% paraformaldehyde-1% glutaraldehyde in 0.1 M 
sodium cacodylate buffer, pH 7.4, treated for 1 hr with 
0.1 M NH4CI to quench free aldehyde groups, and 
washed with cacodylate buffer supplemented with 4.5% 
sucrose (w/v). The cells were scraped from the T flasks 
with a policeman, centrifuged at 800 g for 10 min at 4 °, 
and embedded in 2% low-melting agarose (Seaplaque 
Agarose, FMC Corp., Rockland, MD). After gelification, 
the cell pellets were cut into small blocks (1 ram3), dehy- 
drated in graded ethanol, and embedded in Araldite 502 
or Lowicryl K4M. Thin sections (70-90 nm) were 
mounted on 400-mesh nickel grids and processed for 
immunocytochemical labeling (Garzon et aL, 1982; Gar- 
zon and Bendayan, 1993). The grids were first floated for 
5 min on a drop of TBS (0.05 M Tris-HCI, 0.15 M NaCI, 
pH 8.0), containing 0.05% Tween 20 (TBST), and then 
incubated for 60 rain on a drop of a 200-fold dilution of 
VP8-specific rabbit serum in TBST. The grids were 
washed with TBST and then incubated for 60 min on a 
drop of PAG complex diluted in TBS. Protein A was la- 
beled according to Bendayan (1984) with 10-nm colloidal 
gold particles by the method of Frens (1973). Finally, the 
sections were washed with TBS, rinsed in distilled water 
and counterstained with uranyl acetate and lead citrate. 
Microscopic examination was performed on an EM300 
Philips microscope at 80 kV. The specificity of the label- 
ing was demonstrated by using nonimmune sera, PAG 
complex alone, or mock-infected cells. 
Experimental challenge and reactivation 
Six-month-old Hereford calves were exposed to an 
aerosol of BHV-1 strain 108 as described previously 
(Bielefeldt-Ohman and Babiuk, 1985). Approximately 4 
months after primary infection, animals were treated with 
dexamethasone to reactivate latent virus (Pastoret et aL, 
1980). 
Immunization 
VP8 was purified on a monoclonal antibody column as 
described by van Drunen Littel-van den Hurk and Babiuk 
(1985). With this method, pure preparations of VP8 were 
obtained. Hereford calves were immunized with affinity- 
purified VP8, diluted to a concentration of 100 or 10 #g 
per dose and mixed with Avridine at a ratio of 1=1 as 
described previously (Babiuk et aL, 1987). The animals 
were injected intramuscularly and received two booster 
immunizations at 3-week intervals. The calves were bled 
at the times of immunization and 3 weeks after the last 
immunization for assessment of antibody responses. 
Blood was collected for isolation of peripheral blood 
mononuclear lymphocytes (PBML) and assessment of 
cell-mediated immunity before immunization and 7 days 
after each immunization. 
Enzyme-linked immunosorbent assay (ELISA) 
The antibody responses to VP8 were determined by 
ELISA, essentially as described previously (van Drunen 
Littel-van den Hurk et al., 1984). Polystyrene microtiter 
plates (Immulon 2, Dynatech Laboratories Inc., Alexan- 
dria, VA) were coated with 0.05 #g of affinity-purified 
VP8 or with 0.5 fig of gradient-purified BHV-1 per well. 
Subsequently, the plates were incubated with serially 
diluted bovine sera, followed by horseradish peroxidase- 
conjugated rabbit anti-bovine IgG at a 1,5000 dilution 
(Kirkegaard and Perry Laboratories). ELISA titers were 
expressed as the reciprocal of the highest dilution re- 
suiting in a reading two standard deviations above the 
control value. 
Virus neutralization assay 
The neutralization titers of the VP8-specific bovine sera 
were determined, using 100 PFU of virus, as described 
previously (van Drunen Littel-van den Hurk etaL, 1984). 
The titers were expressed as the reciprocal of the serum 
dilution resulting in a 50% reduction of BHV-1 plaques 
relative to the virus control. 
Isolation of PBML 
Bovine blood was collected into citrate-dextran and 
centrifuged for 30 min at 1000 g. Buffy coat cells were 
aspirated, diluted with an equal volume of RPMI, and 
layered onto FicolI-Paque (Pharmacia LKB Biotechnology 
Inc., Piscataway, N J). After centrifugation for 40 min at 
1000 g, the band of cells at the interface was collected. 
Viability, as assessed by trypan blue exclusion, was 
greater than 95%. 
Blastogenesis assay 
PBML were resuspended in RPMI-1640 medium 
containing 10% FBS (GIBCO) and added to triplicate 
wells of U-bottom 96-well microtiter plates (Coming, 
Richmond Hill, ON, Canada), to which VP8 or uv-irradi- 
ated BHV-1 had been added. Final culture conditions 
consisted of 106 PBML per ml in a volume of 200 #1 
per well. Optimum concentrations of antigen were 1 
#g per ml of VP8 and 106 PFU per ml of BHV-1. Control 
cultures comprised cells cultured in RPMI alone. After 
5 days of stimulation, 0.5 #Ci of [Methy/-3H]thymidine 
(TdR, 5.0 Ci/mmol; Amersham Canada Ltd., Oakville, 
ON, Canada) was added to all wells for the last 18 hr 
of culture. Incorporation of TdR into cellular DNA was 
assessed following harvesting of cells onto glass fi- 
ber filter mats (Skatron, Sterling, VA). 3H incorporation 
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FIG. 1. (A) Localization of VP8 in BHV-1. Gradient-purified BHV-1 
(lanes D and E), treated with 1% NP-40 (lanes A and F) or 1% NP-40 
in 1 M NaCI (lane B and G) and separated by ultracentrifugation into 
supernatant (lanes A, B, F, and G) and pellet (lanes C and H). The 
viral polypeptides were identified by SDS-PAGE (8.5%) under educing 
conditions and stained with Coomassie brilliant blue (lanes A, B, C, 
and D) or transferred to nitrocellulose and probed with VP8-specific 
monoclonal antibody 1G4 (lanes E, F, G, and H). The position of VP8 
is indicated in the margin. The positions of molecular weight markers 
X 10 -3 are shown in the left margin. (B) Carbohydrate detection. Affinity- 
purified VP8, probed with VP8-specific monoclonal antibody (lane A), 
probed with biotinylated Dolichus biflorus lectin (lane B), or oxidized 
with periedate and treated with biotin-hydrazide (lane D). Adenovirus 
hexon was probed with biotinylated Dolichus biflorus lectin (lane O) 
or oxidized with periodate and treated with biotin-hydrazide (lane E). 
Glycoprotein IV was probed with a glV-specific monoclonal antibody 
mixture (lane F) or oxidized with periodate and treated with biotin- 
hydrazide (lane G). 
was measured with a model 1701 liquid scintil lation 
counter (Beckman Instruments, Richmond, BC, Can- 
ada). Results are expressed as a stimulation index 
(mean counts per minute with antigen/mean counts 
per minute without antigen). 
RESULTS 
VP8 is a glycosylated tegument protein 
Treatment with nonionic detergent has been used 
as a means to solubilize BHV-1 polypeptides. Treat- 
ment of purified virions with NP-40 resulted in the 
release of a portion of VP8 into the detergent fraction. 
Further treatment of the pellet fraction with 1% NP-40 
and 1 M NaCI caused more VP8 to dissociate from 
the nucleocapsid fraction, although a portion of VP8 
still remained associated with the pellet (Fig. 1A). The 
association of VP8 with envelope as well as nucleo- 
capsid supports the hypothesis that VP8 is a tegument 
protein (Bolton et al., 1983; Marshall et al., 1986). 
Since VP8 is homologous to VP13/14 of HSV-1, we 
investigated whether VP8 is glycosylated. The pre- 
dicted amino acid sequence of VP8 has no N-linked 
glycosylation sites (Carpenter and Misra, 1991). In 
addition, the presence of tunicamycin during virus in- 
fection does not have an effect on the electrophoretic 
mobility of VP8 (van Drunen Littel-van den Hurk and 
Babiuk, 1985), confirming that VP8 does not contain 
any N-linked oligosaccharides. Previous studies have 
shown that it is not possible to label VP8 with [3H]- 
glucosamine. However, carbohydrate was detected 
on VP8 following periodate oxidation (Fig. 1B). Out of a 
range of different lectins with specificities for different 
carbohydrate groups, only Dol ichus b i f lorus lectin 
[specific for N-acetyl galactosamine (GalNAc)-~- 
3GalNAc] bound to VP8 (Fig. 1B). This indicates that 
VP8 contains O-linked carbohydrate. No carbohydrate 
was detected on the hexon protein of hemorrhagic 
enteritis virus, an unglycosylated structural protein, 
whereas carbohydrate was observed on BHV-1 glV. 
Intracellular distribution of VP8 
In order to determine the localization of VP8 during 
the course of an infection, MDBK cells were infected 
with BHV-1 and VP8 was identified by indirect immune- 
fluorescence (Fig. 2). Before infection, no staining was 
observed. As early as 2 hr postinfection, VP8 was iden- 
tified in the nucleus of the infected cell (Fig. 2B). The 
intensity of the nuclear staining increased until 6 hr 
after infection, indicating transport of input VP8 into 
the nucleus (Fig. 2D). Small amounts of VP8 were found 
in the cytoplasm from about 6 to 10 hr after infection 
(Figs. 2D and 2E). The amount of VP8 continued to 
increase both in the nucleus and in the cytoplasm until 
14 hr after infection, which is probably due to de novo 
synthesis (Fig. 2F) (Carpenter and Misra, 1991). In con- 
trast, the early glycoprotein glV was observed in the 
cytoplasm from 4 hr postinfection (Fig. 2G). Later dur- 
ing infection, increasing amounts of glV accumulated 
in the cytoplasm and on the plasma membranes of the 
infected cells (Fig. 2H and 21). Glycoprotein IV was 
never observed in the nucleus. From 14 until 24 hr 
postinfection, the intensity of the VP8 and glV staining 
did not change. 
Ultrastructurat localization of VP8 in infected cells 
BHV-l-infected MDBK cells were incubated with 
VP8-specific rabbit serum, followed by protein A-gold 
complex (Fig. 3A). Gold labeling was observed in the 
nucleus over dense areas surrounding the nucleocap- 
sids, in the cytoplasm over dense structures, and in 
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Fre. 2. Time course of VP8 expression in BHV-l-infected MDBK cells. The localization of VP8 was determined by indirect immunofluorescence 
with a specific polyclonal rabbit serum at time points 0 hr (before infection) (A), 2 hr (B), 4 hr (C), 6 hr (D), 10 hr (E), and 14 hr (F) after BHV-1 
infection. A glV-specific monoclonal antibody mixture was used as a control at time points 4hr (G), 8 hr (H) and 14 hr (I). Magnification, X175. 
the Golgi area. VP8 was not present on the cell surface, 
which confirms that VP8 is not expressed on the 
plasma membrane. However, it was found along the 
cytoplasmic membranes over budding virus particles. 
Virus particles released from infected cells are shown 
in Figs 3B-D. Figure 3B shows the typical morphology 
of BHV-1 virions at different section levels. Intact and 
partially disrupted virions were gold-labeled in be- 
tween the nucleocapsid and the envelope, again sug- 
gesting a tegument localization of VP8. However, some 
of the gold particles appeared associated with the sur- 
face of the virion (Figs. 3C and 3D). 
In the nucleus, the immunogold label appeared to 
be concentrated in dense areas surrounding a large 
number of nucleocapsids (Fig. 4A). High concentra- 
tions of VP8-specific label were also found along the 
nuclear membrane, suggesting transport of VP8 
through the membrane (Fig. 4B). In the cytoplasm, the 
VP8-specific label was primarily localized over dense 
material, which accumulates progressively in the cis- 
ternae of the Golgi (Fig, 5A). Numerous nucleocapsids 
or enveloped virus particles were included in these 
heavily labeled structures (Figs. 5B and 5C). Enveloped 
virus particles were also observed in Golgi-derived cy- 
toplasmic vesicles. Intracytoplasmic dense bodies, 
which have also been described for HOMV, were 
strongly labeled, suggesting that they may consist of 
excess VP8 (Fig. 50). The passage or accumulation of 
VP8 in the Golgi was confirmed by the colocalization 
of VP8 (VP8-specific serum and protein A-gold,  5 mm) 
418 VAN DRUNEN LITTEL-VAN DEN HURK ET AL. 
FIG. 3. Postembedding immunolocalization of VP8 in BHV-l-infected cells and virions. VP8 was detected with VP8-specific rabbit serum and 
protein A gold (10 rim). (A) VP8-specific gold label was localized in the nucleus (N) in dense areas around nucleocapsids (c), in the cytoplasm 
over dense structures (arrow), in the Gotgi (G) area (arrowhead), and along the cytoplasmic membrane over the budding virus particles (v). The 
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Fie. 4. Nuclear immunolocalization of VP8 in BHV-1 infected cells. (A) The nuclear dense material surrounding the nucleocapsids was heavily 
labeled (short arrowhead). (B) VP8-specific gold label was also present on the nuclear membrane (short arrowheads) around budding of nucleocapsids 
(long arrowheads). The bar represents 0.2 #m. 
bar represents 1 #m. (B) UItrastructural morphology, typical for BHV-1 shown at the different section levels of the particle from tangential (long 
arrowhead) to transversal (short arrowhead) plane. (C) and (D) VPS-specific label, localized over the tegument (t) of the virus (v) in between the 
nucleocapsid (c) and the envelope (env). The bar represents 0.1 #m. 
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FIG. 5, Intracyplasmic immunolocalization of VP8 in BHV-l-infected cells. (A) VP8-specific gold label was most prevalent in association with dense 
material, which accumulates progressively in the cisternae of the Golgi (G), (B) and (C) Numerous nucleocapsids or enveloped viral particles were 
included in the heavily labeled structures. (D) The passage of VP8 in the Golgi (G) was confirmed by the colocalization of VP8 (VP8-specific rabbit 
serum and protein A-gold, 5 nm, arrows) and galactose (Ricinus communis agglutinin-gold, 15 nm, arrowhead s) in the Golgi area and over virus 
particles transported through the Golgi or budding on the cytoplasmic membrane. The bar represents 0.2 /~m. 
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FIG. 6. VP8-specific immune responses of calves challenged with BHV-1 (A) Proliferative response to VP8 (B) and BHV-1 (m) in BHV-l-challenged 
animals. (B) Proliferative response to VP8 (n) and BHV-1 ([]) in control animals. (C) VP8-specific ELISA titers, expressed as the reciprocal of the 
highest dilution resulting in a reading of two standard deviations above the control value. Error bars show the standard deviation of the mean of 
10 animals. (D) VP8-specific reaction on a Western blot on Days 0 (lane A), 24 (lane B), 105 (lane C), and 126 (lane D) after challenge. Reactivation 
occurred on Day 105. Purified VP8 was transferred from a 8.5% polyacrylamide gel to nitrocellulose, which was then probed with the different 
bovine sera. The reaction of a VP8-specific monoclonal antibody (lane E) is shown on the right. 
and galactose (Ricinus communis agglutinin-gold, 15 
mm) in the Golgi area and over virus particles trans- 
ported through the Golgi or budding through the cyto- 
plasmic membranes (Fig. 5D). No immunogold label 
was observed in mock-infected cells or in BHV-I-in- 
fected cells treated with nonimmune serum or PAG 
complex alone. 
VP8-specific immune responses 
To examine the presence of VP8-specific cellular and 
humeral immunity, calves were challenged with BHV-1, 
and the virus was reactivated 4 months later. When 
PBMC from BHV-l-challenged animals were cultured in 
the presence of VP8 or BHV-1, antigen-specific prolifera- 
tion was enhanced 7 days after challenge. The prolifera- 
tive responses continued to increase until 49 days after 
challenge (Fig. 6A). Antigen-specific proliferation was not 
observed in control animals (Fig. 6B). VP8-specific anti- 
bodies were detected by ELISA as early as 4 days after 
challenge. The levels of VP8-specific antibody continued 
to rise until 8 days postinfection. Following dexametha- 
sone treatment on Day 105, the meanwhile reduced VP8- 
specific antibody titers increased again (Fig. 60). The 
specificity of the immune response was confirmed by 
Western blotting (Fig. 6D). 
Immunogenicity of VP8 
Since VP8, which is the most abundant protein in 
the virion, was recognized by PBMC and antibodies 
of BHV-1 hyperimmune animals, its immunogenicity in 
cattle was assessed. Calves were immunized with 100 
or 10 #g of affinity-purified VP8 (Fig. 7A). After two 
immunizations with 100 #g of VP8, serum neutralizing 
antibody levels were enhanced, with a further increase 
following the third immunization. In contrast, with 10 
#g of VP8 two doses were needed, before neutralizing 
antibody titers started to increase (Fig. 7B). To deter- 
mine whether T lymphocytes were stimulated by immu- 
nization of calves with VP8, the proliferative response 
of PBMC, cultured in the presence of VP8 or BHV-1, 
was measured in vitro. Animals immunized with 100 
#g of VP8 showed an enhanced proliferative response 
as early as 7 days after the first immunization. This 
response continued to rise until after the last immuni- 
zation (Fig. 70). However, three doses of 10 #g of VP8 
were needed for an appreciable increase in prolifera- 
tion to occur (Fig. 7D). The immune response was VP8- 
specific as shown by ELISA (Fig. 7E). In contrast, none 
of the animals reacted with gl, gll (not shown), gill, or 
glV (Fig. 7F)in an ELISA. In addition, BHV-1 hyperim- 
mune sera recognized the major glycoproteins gl, gill, 
and glV, as well as several other BHV-1 proteins, 
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whereas the sera from the VP8-immunized animals 
only recognized VP8 in Western blot and immunopre- 
cipitation assays, further proving that they were not 
accidentally exposed to BHV-1 or other viral proteins 
during the immunization period (Figs. 7G and 7H). 
DISCUSSION 
VP8 is one of the most abundant proteins in BHV-1- 
infected cells and virions. However, little is known 
about its structural and functional properties. In this 
study we determined the ultrastructural ocalization of 
VP8 in the virions and virus-infected cells, as well as 
the interactions between VP8 and the host's immune 
system. 
In the virions, VP8 was found in the tegument. It was 
partially extracted with nonionic detergent and partially 
with buffer of neutral pH and high ionic strength, indi- 
cating that this protein is associated with capsid and 
tegument proteins by ionic interactions. VP8 appeared 
less strongly associated with the nucleocapsid than 
its HSV homologue VP13/14, which was not released 
at all by nonionic detergent reatment (Meredith et aL, 
1991). The localization of VP8 in the tegument was 
confirmed by electron microscopy. 
In the virus-infected cells, VP8 was found in the nu- 
cleus as early as 2 hr postinfection, suggesting that 
this gamma2 protein is not newly synthesized within 
the cells, but acquired from the inoculum. The phenom- 
enon of uptake and subsequent detectable nuclear lo- 
calization of a viral protein before virus replication has 
been reported for human cytomegalovirus (HCMV) 
pp65, one of the viral tegument proteins (Grefte et aL, 
1992). One reason for the abundance of VP8 in the 
tegument may be this early transport to the nucleus 
and the need for sufficient quantities of this protein to 
carry out its function, which, in analogy to the role of 
the HSV homologue VP13/14 (McKnight et aL, 1987; 
Zhang et aL, 1991), may be modulation of alpha gene 
expression. Later during infection, VP8 was also pres- 
ent in the cytoplasm and more VP8 accumulated in the 
nucleus. This indicates that de novo-synthesized VP8 
is also transported into the nucleus late during the 
infectious cycle. It is likely that at this time VP8 has 
another function. In the nucleus, VP8 was primarily 
found in dense inclusions and surrounding nucleocap- 
sids which may indicate tegument formation. If VP8 
is indeed complexed with the nucleocapsids in the 
nucleus, it may also function in the translocation of 
nucleocapsids to the cytoplasm, where large quanti- 
ties of VP8 were found in dense inclusions and around 
nucleocapsids, while they move through the Golgi. In 
the cytoplasm, as well as in the nucleus, VP8 was 
present in abundance, indicating the importance of 
sufficient quantities of VP8 in the tegument. 
In cattle, VP8 was recognized following challenge 
with BHV-1, both by T cells and by antibodies, indicat- 
ing the potential of VP8 to act as an immunogen during 
infection. This was confirmed by the ability of purified 
VP8 to induce low levels of neutralizing antibodies and 
T cell activation in cattle. Although the VP8-specific 
neutralizing antibody titers were lower than those in- 
duced by glycoproteins gill (gO) and glV (gD), they 
were similar to those induced by gl (gB) (Babiuk et aL, 
1987; van Drunen Littel-van den Hurk et aL, 1990). In 
addition, VP8 induced a stronger cell-mediated im- 
mune response than gl or gl.li (Hutchings eta/., 1990). 
The ability of VP8 to induce antibodies in cattle that 
neutralize virus infection agrees with a previous report 
by Collins et al. (1984), who generated a VP8-specific 
neutralizing monoclonal antibody. These data suggest 
that VP8 may be partially exposed on the virion. Neu- 
tralization by VP8-specific antibodies probably occurs 
postattachment, perhaps during uncoating of the vi- 
rion. Another potential mechanism of neutralization by 
VP8-specific antibodies could involve inhibition of VP8- 
induced modulation of alpha gene expression. 
The sequence of VP8 has been shown to be homolo- 
gous to those of VP13/14 of HSV(Carpenter and M isra, 
1991; Davison and Scott, 1986) and gpl0 of EHV (Whit- 
taker etaL, 1991). In addition, we have shown that VP8, 
like VP13/14 and gpl0, contains O-linked carbohy- 
drates, which is apparently acquired during transport 
of tegumented nucleocapsid s through the Golgi. Al- 
though the role of this type of modification to virus 
structural proteins is not clear, carbohydrate residues 
appear to be common on proteins involved in transcrip- 
tional control (Jackson and Tijan, 1988). BHV-1 VP8 
also resembles HCMV pp65 in many ways. These pro- 
teins are both transported to the nucleus early after 
infection and are both phosphorylated (Meredith et al., 
1991; Whittaker et aL, 1991). Furthermore, like VP8, 
pp65 has been reported to be a major target of the 
cell-mediated immune response (Forman et aL, 1985) 
during natural infection with HCMV. The pp65 protein 
also causes a humoral immune response in animals 
as well as in humans, albeit not as strongly as some 
of the other HCMV antigens (Gibson and Irmiere, 1984). 
In this study we demonstrated expression and local- 
ization of VP8 in the virions and virus-infected cells. 
VP8 clearly has a function in the nucleus early after 
infection, which may account for its abundance in the 
virion, as well as late during infection, which may ex- 
with VP8-specific monoclonal antibody 1G4 (lane A) or bovine sera before (lane B) and after (lane C) immunization with 100 #g of VP8 or before 
(lane D) and after (lane E) immunization with 10 #g of VP8. The immunoprecipitates were analyzed by electrophoresis under reducing conditions. 
The position of VP8 is indicated in the left margin. The positions of molecular weight markers xl0 -3 are shown in the right margin. 
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plain the abundant de novo synthesis in the infected 
cells. In addition, VP8 was shown to be a good immu- 
nogen in cattle, specifically for the induction of cell- 
mediated immunity. 
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